Literature DB >> 26080835

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Francesca Cottini1, Teru Hideshima2, Rikio Suzuki2, Yu-Tzu Tai2, Giampaolo Bianchini3, Paul G Richardson2, Kenneth C Anderson4, Giovanni Tonon5.   

Abstract

UNLABELLED: Ongoing DNA damage is a common feature of epithelial cancers. Here, we show that tumor cells derived from multiple myeloma, a disease of clonal plasma cells, demonstrate DNA-replicative stress, leading to DNA damage. We identified a poor-prognosis subset of multiple myeloma with extensive chromosomal instability and replicative stress, which rely on ATR to compensate for DNA-replicative stress; conversely, silencing of ATR or treatment with a specific ATR inhibitor triggers multiple myeloma cell apoptosis. We show that oncogenes, such as MYC, induce DNA damage in multiple myeloma cells not only by increased replicative stress, but also via increased oxidative stress, and that reactive oxygen species-inducer piperlongumine triggers further DNA damage and apoptosis. Importantly, ATR inhibition combined with piperlongumine triggers synergistic multiple myeloma cytotoxicity. This synthetic lethal approach, enhancing oxidative stress while concomitantly blocking replicative stress response, provides a novel combination targeted therapy to address an unmet medical need in this subset of multiple myeloma. SIGNIFICANCE: Multiple myeloma remains an incurable disease. We have identified a subset of multiple myeloma patients with poor prognosis, whose tumors present chromosomal instability, replicative and oxidative stress, and DNA damage. We define a synthetic lethal approach enhancing oxidative stress while targeting replicative stress response, inducing tumor cell apoptosis in this patient subset. Cancer Discov; 5(9); 972-87. ©2015 AACR.This article is highlighted in the In This Issue feature, p. 893. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26080835      PMCID: PMC4560623          DOI: 10.1158/2159-8290.CD-14-0943

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  57 in total

1.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.

Authors:  Matilde Murga; Stefano Campaner; Andres J Lopez-Contreras; Luis I Toledo; Rebeca Soria; Maria F Montaña; Luana D' Artista; Thomas Schleker; Carmen Guerra; Elena Garcia; Mariano Barbacid; Manuel Hidalgo; Bruno Amati; Oscar Fernandez-Capetillo
Journal:  Nat Struct Mol Biol       Date:  2011-11-27       Impact factor: 15.369

2.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

3.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Authors:  Paola Neri; Li Ren; Kathy Gratton; Erin Stebner; Jordan Johnson; Alexander Klimowicz; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Sagar Lonial; Lawrence H Boise; Nizar J Bahlis
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

4.  Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.

Authors:  J Bartkova; P Hamerlik; M-T Stockhausen; J Ehrmann; A Hlobilkova; H Laursen; O Kalita; Z Kolar; H S Poulsen; H Broholm; J Lukas; J Bartek
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

7.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

8.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

9.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Replication stress links structural and numerical cancer chromosomal instability.

Authors:  Rebecca A Burrell; Sarah E McClelland; David Endesfelder; Petra Groth; Marie-Christine Weller; Nadeem Shaikh; Enric Domingo; Nnennaya Kanu; Sally M Dewhurst; Eva Gronroos; Su Kit Chew; Andrew J Rowan; Arne Schenk; Michal Sheffer; Michael Howell; Maik Kschischo; Axel Behrens; Thomas Helleday; Jiri Bartek; Ian P Tomlinson; Charles Swanton
Journal:  Nature       Date:  2013-02-28       Impact factor: 49.962

View more
  51 in total

1.  p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Francesca Cottini; Yoshihisa Nozawa; Hyuk-Soo Seo; Hiroto Ohguchi; Mehmet K Samur; Diana Cirstea; Naoya Mimura; Yoshikazu Iwasawa; Paul G Richardson; Nikhil C Munshi; Dharminder Chauhan; Walter Massefski; Teruhiro Utsugi; Sirano Dhe-Paganon; Kenneth C Anderson
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

2.  A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.

Authors:  Zhaojun Qiu; Pengyan Fa; Tao Liu; Chandra B Prasad; Shanhuai Ma; Zhipeng Hong; Ernest R Chan; Hongbing Wang; Zaibo Li; Kai He; Qi-En Wang; Terence M Williams; Chunhong Yan; Steven T Sizemore; Goutham Narla; Junran Zhang
Journal:  Cancer Res       Date:  2020-06-10       Impact factor: 12.701

3.  Progress and Paradigms in Multiple Myeloma.

Authors:  Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

4.  ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Authors:  Matteo Marchesini; Yamini Ogoti; Elena Fiorini; Anil Aktas Samur; Luigi Nezi; Marianna D'Anca; Paola Storti; Mehmet Kemal Samur; Irene Ganan-Gomez; Maria Teresa Fulciniti; Nipun Mistry; Shan Jiang; Naran Bao; Valentina Marchica; Antonino Neri; Carlos Bueso-Ramos; Chang-Jiun Wu; Li Zhang; Han Liang; Xinxin Peng; Nicola Giuliani; Giulio Draetta; Karen Clise-Dwyer; Hagop Kantarjian; Nikhil Munshi; Robert Orlowski; Guillermo Garcia-Manero; Ronald A DePinho; Simona Colla
Journal:  Cancer Cell       Date:  2017-06-29       Impact factor: 31.743

5.  Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Authors:  Deepika Sharma Das; Abhishek Das; Arghya Ray; Yan Song; Mehmet Kemal Samur; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

6.  Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Authors:  Jason P W Carey; Cansu Karakas; Tuyen Bui; Xian Chen; Smruthi Vijayaraghavan; Yang Zhao; Jing Wang; Keith Mikule; Jennifer K Litton; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

7.  Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.

Authors:  Abby M Green; Konstantin Budagyan; Katharina E Hayer; Morgann A Reed; Milan R Savani; Gerald B Wertheim; Matthew D Weitzman
Journal:  Cancer Res       Date:  2017-06-27       Impact factor: 12.701

8.  Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

Authors:  Debora Soncini; Paola Minetto; Claudia Martinuzzi; Pamela Becherini; Valeria Fenu; Fabio Guolo; Katia Todoerti; Giovanni Calice; Paola Contini; Maurizio Miglino; Giulia Rivoli; Sara Aquino; Alida Dominietto; Antonia Cagnetta; Mario Passalacqua; Santina Bruzzone; Alessio Nencioni; Massimo Zucchetti; Tommaso Ceruti; Antonino Neri; Roberto M Lemoli; Michele Cea
Journal:  Blood Adv       Date:  2020-09-22

9.  A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Authors:  Arghya Ray; Durgadevi Ravillah; Deepika S Das; Yan Song; Eva Nordström; Joachim Gullbo; Paul G Richardson; Dharminder Chauhan; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2016-04-20       Impact factor: 6.998

10.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice.

Authors:  Lei Wang; Munish Kumar; Qipan Deng; Xu Wang; Ming Liu; Zhaojian Gong; Shanshan Zhang; Xiaodong Ma; Zijun Y Xu-Monette; Min Xiao; Qing Yi; Ken H Young; Kenneth S Ramos; Yong Li
Journal:  Cancer Lett       Date:  2018-10-19       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.